• D-Pharm Ltd., of Rehovot, Israel, said it received approval from regulatory authorities in Slovakia to start a Phase II study testing DP-b99 in patients with acute high-risk inflammation of the pancreas. The trial will enroll about 30 patients who will be treated twice daily with either DP-b99 or placebo and followed up using clinical assessment scales, by monitoring inflammatory biomarkers and with abdominal imaging.